文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移患者早期整合神经心理照护:ATHENA随机对照试验

Early Integrated Neuropsychological Care for Patients With Brain Metastases: A Randomized Controlled Trial (ATHENA Trial).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-18

这项2期随机对照试验纳入110例接受放疗的脑转移患者,1:1分配至神经心理整合组或标准照护组,主要终点为放疗后3个月FACT-Br生活质量变化,结果未达主要终点(估计差值0.27,P=.15),探索性分析显示9个月时整合组FACT-Br评分更高(0.63,P=.006),神经认知功能两组无差异。

要点

  • 放疗后3个月FACT-Br生活质量主要终点未达到。
  • 9个月探索性分析显示整合组FACT-Br评分较高。
  • 两组神经认知功能评估未见差异。

核心结论

  • 放疗后3个月改善FACT-Br生活质量的主要终点未达到。
  • 探索性分析提示较晚时间点整合组生活质量可能获益。

研究设计与样本

  • 2期随机对照试验,放疗科脑转移患者1:1随机分为神经心理整合组与标准照护组。
  • 神经心理整合为放疗开始前起3个月内共5次预约。
  • 2022年8月至2024年6月共入组110例,中位年龄62.5岁(IQR 54-70),中位KPS 90(IQR 80-90)。

主要发现

  • 主要终点未达到:FACT-Br估计差值0.27,SE=0.19,P=.15。
  • 9个月探索性分析中整合组FACT-Br评分更高(0.63,P=.006)。
  • 神经认知功能两组无差异。

关键数值与推荐

  • 主要终点为放疗完成后3个月FACT-Br生活质量变化。
  • 生活质量采用FACT-Br及EORTC QLQ评估,认知采用HVLT-R、COWAT、TMT A/B评估。
  • 抑郁采用PHQ-9、焦虑采用GAD-7评估。

临床怎么用

  • 早期整合神经心理照护未在3个月改善生活质量,不应据此作为标准照护推广。
  • 晚期生活质量潜在获益需进一步验证。

局限性

  • 为2期随机试验,样本量110例。
  • 9个月生活质量差异为探索性分析。
  • 中位随访21.1个月(95%CI 16.2-25.5)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Decline of quality of life (QOL) and cognitive function is common for patients with brain metastases receiving radiation therapy, but there is currently no standard of care for addressing those symptoms. This phase 2 randomized controlled trial examined the efficacy of early neuropsychological evaluation and integration to preserve QOL and cognition for patients treated with radiation for brain metastases. METHODS AND MATERIALS: Patients with brain metastases seen in a radiation oncology department were eligible for inclusion and randomized 1:1 to neuropsychology integration versus standard of care. The neuropsychology integration involved 5 appointments over a 3-month period beginning prior to radiation therapy treatment initiation. QOL was measured with Functional Assessment of Cancer Therapy - Brain (FACT-Br) and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire assessments. Cognition was measured by the Hopkins Verbal Learning Test-Revised, Controlled Oral Word Association Test, and Trail Making Test A/B. Depression (Patient Health Questionnaire-9) and anxiety (General Anxiety Disorder-7) assessments were also collected. The primary endpoint was change in QOL 3 months after completion of radiation therapy, measured by FACT-Br. Longitudinal outcomes were analyzed using linear mixed-effects models adjusting for baseline score and radiation type. RESULTS: From August 2022 to June 2024, 110 patients were enrolled. The median age and Karnofsky Performance Status were 62.5 (IQR, 54-70) and 90 (IQR, 80-90), respectively. A plurality of patients (43%) had primary lung cancer, and most patients (74%) had ≤15 brain metastases. With a median follow-up of 21.1 months (95% CI, 16.2-25.5), the primary endpoint was not met (estimated difference 0.27, SE = 0.19, P = .15). In exploratory analyses at 9 months, FACT-Br scores were higher in the integration arm (0.63, P = .006). There were no differences in neurocognitive function between arms. CONCLUSIONS: In this phase 2 randomized trial, the primary endpoint of improved FACT-Br QOL at 3 months after radiation therapy was not met. Exploratory findings at later timepoints suggest potential benefits in QOL.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Perlow HK, Dawson EL, Sun Y, et al. Early Integrated Neuropsychological Care for Patients With Brain Metastases: A Randomized Controlled Trial (ATHENA Trial). Int J Radiat Oncol Biol Phys. 2026. PMID: 42471047. doi:10.1016/j.ijrobp.2026.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。